Home  |  Contact

UniProtKB/Swiss-Prot P13569: Variant p.Pro1013Leu

Cystic fibrosis transmembrane conductance regulator
Gene: CFTR
Variant information

Variant position:  1013
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Proline (P) to Leucine (L) at position 1013 (P1013L, p.Pro1013Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CF.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  1013
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1480
The length of the canonical sequence.

Location on the sequence:   DFIQLLLIVIGAIAVVAVLQ  P YIFVATVPVIVAFIMLRAYF
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         DFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYF

Gorilla                       DFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYF

                              DFIQLLLIVIGAVAVVSVLQPYIFLATVPVIAAFIILRAYF

Rhesus macaque                DFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYF

Chimpanzee                    DFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYF

Mouse                         DFIQLVFIVIGAIIVVSALQPYIFLATVPGLVVFILLRAYF

Rat                           DFIQLLFIVVGAIIVVSALQPYIFLATVPGLAVFILLRAYF

Pig                           DFIQLLLIVIGAVAVVSVLKPYIFLATVPVIVAFILLRAYF

Bovine                        DFVQLLLIVIGAVVVVSVLQPYIFLATVPVIAAFILLRAYF

Rabbit                        DFIQLLLIVVGAIAVVSVLQPYIFLATVPVIAAFILLRAYF

Sheep                         DFIQLLLIVIGAVVVVSVLQPYIFLATVPVIAAFILLRGYF

Horse                         DFIQLLLIVIGAVAVVSVLQPYIFLATVPVIAAFIILRAYF

Xenopus laevis                DLTQLVLIVIGAITVVSLLEPYIFLATVPVIVAFILLRSYF

Zebrafish                     DFVQLTVVVVGCILVVSIVRPYIFLAATPLAIIFIVMRKYF

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1480 Cystic fibrosis transmembrane conductance regulator
Topological domain 1012 – 1013 Extracellular
Domain 859 – 1155 ABC transmembrane type-1 2
Alternative sequence 606 – 1480 Missing. In isoform 3.


Literature citations

Analysis of the CFTR gene in Turkish cystic fibrosis patients: identification of three novel mutations (3172delAC, P1013L and M1028I).
Onay T.; Topaloglu O.; Zielenski J.; Gokgoz N.; Kayserili H.; Camcioglu Y.; Cokugras H.; Akcakaya N.; Apak M.; Tsui L.-C.; Kirdar B.;
Hum. Genet. 102:224-230(1998)
Cited for: VARIANTS CF LEU-1013 AND ILE-1028;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.